Company: LENZ
Filing Date: 2025-04-04
Form Type: POS AM
Source: 0001628280-25-016813
Chunk: 26

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-04
Form: POS AM
Chunk 26
---
 amended, which we refer to as the “Exchange Act” in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.

You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:

<div align='center'>LENZ Therapeutics, Inc.

201 Lomas Santa Fe Dr., Suite 300

Solana Beach, California 92075

(858) 925-7000</div>

Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.

<div align='center'>18</div>

# PART II

### INFORMATION NOT REQUIRED IN PROSPECTUS

## ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table sets forth all expenses to be paid by the Registrant, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates.

| SEC registration fee              |     | $ |   3,128 |     | -1 |
| FINRA filing fee                  |     |   |       — |     |    |
| Printing and engraving            |     |   |         |     |  * |
| Legal fees and expenses           |     | $ | 100,000 |     |    |
| Accounting fees and expenses      |     | $ | 270,000 |     |    |
| Transfer agent and registrar fees |     |   |         |     |  * |
| Miscellaneous                     |     |   |         |     |  * |
| Total                             |     | $ | 373,128 |     |    |

__________________

(1) Previously paid.

* These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time.

## ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 145 of the DGCL authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened